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1. Introduction 
In the elderly, Alzheimer’s disease (AD) is the most common form of dementia (Hebert et 
al., 2003). The two pathologies that characterize the disease are the presence of large 
numbers of intracellular neurofibrillary tangles (NFTs) and extracellular neuritic plaques in 
the brain (e.g., Braak and Braak, 1991; 1998; Selkoe, 2001). Neurofibrillary tangles consist of 
hyperphosphorylated, twisted filaments of the cytoskeletal protein tau (e.g., Duff, 2006), 
whereas plaques are primarily made up of amyloid ǃ(Aǃ [Selkoe, 2001; Dickson and 
Vickers, 2002]), a 39-43 amino acid long peptide derived from the proteolytic processing of 
the amyloid precursor protein (APP [Selkoe, 2001; Vetrivel and Thinakaran, 2006]). When 
APP is sequentially cleaved by the ǃ-secretase and Ǆ-secretase, one of the resulting 
breakdown product is Aǃ, in contrast, initial cleavage by ǂ-secretase (in the middle of the 
Aǃ sequence) leads to production of APPsǂ and the C83 peptide (Selkoe, 2001). 
Most cases of AD are sporadic, however approximately 5 % of AD cases are familial (Price 
and Sisodia, 1995; Selkoe, 2001), these cases are related to mutations in the genes for APP, 
and presenilin 1 and 2 (PS1 and PS2 [Price and Sisodia, 1995; Hardy, 1997; Selkoe, 2001]). 
Transgenic mice expressing mutated human AD genes offer a powerful model to study the 
role of Aǃ in the development of pathology (e.g., Duff and Suleman, 2004; McGowan et al, 
2006). The present study employs three lines of transgenic mice expressing both human 
APPswe and/or PS1 mutations. These lines of mice develop elevated levels of Aǃ42 at 
different ages, and at different locations (Van Groen et al., 2005; Wang et al., 2003).  
2. Materials and methods 
2.1 Animals 
Two lines of APP and PS1 single and double transgenic mice (AP/PS) were used in the 
present study. The first line of mice was generated from matings between APPswe and 
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HuPS1-A246E transgenic mice, this mouse line was originally produced at the Johns 
Hopkins University (Borchelt et al., 1996), and was bred locally on a C57BL/6J background. 
The second line of APP/PS1 mice was the APPswe+PS1Δ9 line, originally produced at the 
Johns Hopkins University (Jankowsky et al., 2001), we acquired these mice from JAX at the 
age of six weeks. The animals were housed 4/cage in our facility; in a controlled 
environment (temperature 22oC, humidity 50-60%, light from 07:00-19:00), with food and 
water were available ad libitum. All procedures were conducted in accordance with the local 
Institutional Animal Care and Use Committee (IACUC) guidelines. 
2.2 Peptides 
In short, a mirror image phage display approach was used to identify novel and highly 
specific ligands for Alzheimer's disease amyloid peptide Aǃ1-42 (Wiesehan et al., 2003). In 
short, a randomized 12-mer peptide library presented on M13 phages was screened for 
peptides with binding affinity for the mirror image of Aǃ1-42 (Wiesehan et al., 2003). After 
four rounds of selection and amplification the peptides were enriched with a dominating 
consensus sequence. The mirror image of the most representative peptide (i.e., D1) was 
shown to bind Aǃ1-42 with a dissociation constant in the submicromolar range (Wiesehan et 
al., 2003). The D2 and D3 peptides come from two other phage display selections against 
Aǃ42. The D1 peptide has a higher affinity for Aǃ42 monomers, D2 has a low specificity, 
whereas D3 has a high affinity for Aǃ42 oligomers  (Funke et al,  2010). To study the binding 
characteristics of the D-peptides in more detail, an L-peptide version of the D1-peptide was 
made, and a scrambled (sequence) peptide of similar length was also made. In the binding 
experiments the peptides that were used had been conjugated with a FITC molecule for 
visualization purposes, except in a few experiments. In those experiments D1 conjugated 
with other fluorophores were tested to study the interaction of the fluorescent moiety with 
binding characteristics of the D1 peptide.  
2.3 Histopathological techniques 
In short, mice were anesthetized, transcardially perfused with saline followed by 4% 
paraformaldehyde and the brains were removed from the skull. After postfixation (4h) and 
cryoprotection (24h in 30% sucrose), six series (1 in 6) of coronal sections were cut through 
the brain. The first series of sections was mounted unstained, and the second, third and 
fourth series were stained immunohistochemically according to published protocols (Kadish 
et al., 2002; Van Groen et al., 2006) the other two series were stored in at -20oC in antifreeze 
for future analysis. One half of the second series was stained for human Aǃ using the W0-2 
antibody (mouse anti-human Aǃ4-9; Ida et al., 1996), the other half of the second series was 
stained for mouse Aǃ (rabbit anti-rodent Aǃ; Covance; Van Groen et al, 2006). The first half 
of the third series was stained for Aǃ40 (mouse anti-Aǃ40, Covance) the other half for Aǃ42 
(mouse anti-Aǃ42; Covance). In some animals, one half of the fourth series was stained for 
GFAP (mouse anti-GFAP; Sigma), whereas the other half was stained for CD11b (rat anti-
mouseCD11b; Serotec), a marker of microglia, to analyze inflammation in the brain. Some of 
these sections were double stained with either Congo red, thioflavine S or thiazine red to 
visualise ǃ sheets, i.e., Aǃ plaque cores in our material, in a few animals methoxy-X04 
(Klunk et al., 2002) was infused during the perfusion to label all Aǃ in the brain. The 
sections destined for immunohistochemical Aǃ staining were pretreated for 30 min with hot 
(85oC) citrate buffer. The series of sections were transferred to a solution containing the 
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primary antibody (W0-2, mouse monoclonal), this solution consists of TBS with 0.5 % Triton 
X-100 added (TBS-T). Following incubation in this solution for 18 h on a shaker table at 
room temperature (20oC) in the dark, the sections were rinsed three times in TBS-T and 
transferred to the solution containing the appropriate secondary antibody (goat anti-
mouse*biotin; Sigma). After two hours, the sections were rinsed three times with TBS-T and 
transferred to a solution containing mouse ExtrAvidin® (Sigma), following rinsing the 
sections were incubated for approximately 3 min with Ni-enhanced DAB (Kadish et al., 
2002). In a small number of sections, the Aǃ deposits were double labeled for Aǃ40 and 
Aǃ42 using fluorescent secondary antibodies. All stained sections were mounted on slides 
and coverslipped.  
Histochemical stains. Thioflavine-S staining (Guntern et al, 1982), sections are mounted on 
gelatinized slides, and air-dried. When dry the slides are immersed in distilled water for 5 
min twice to rehydrate, then they are immersed in the Thioflavine-S solution (1g of 
Thioflavine-S in 100 ml distilled water) for 20 min. Then the slides are rinsed quickly twice 
in distilled water and air dried, when dry they are rinsed in xylene, and coverslipped with 
DPX. The staining procedure is performed in the dark, i.e., the solution of Thioflavine-S is 
kept in a opaque container, similarly the staining procedure is done in opaque containers. 
Thioflavine-T staining (Morimatsu et al, 1975), sections are mounted on gelatinized slides, 
and air-dried. When dry the slides are immersed in distilled water for 5 min twice to 
rehydrate, then they are immersed in the Thioflavine-T solution (1g of Thioflavine-T in 100 
ml distilled water) for 20 min. Then the slides are rinsed quickly twice in distilled water and 
air dried, when dry they are coverslipped with DPX. The staining procedure is performed in 
the dark, i.e., the solution of Thioflavine-T is kept in a opaque container, similarly the 
staining procedure is done in opaque containers. Congo red staining (Glenner, 1981), slides 
with brain sections are put overnight in 4% paraformaldehyde solution, the next day slides 
are rinsed twice with distilled water for 5 min, then put in the pretreatment solution (a 80% 
ethanol saturated NaCl solution with 1% sodium hydroxide added [1ml per 100 ml) for 20 
min. Then the slides are transferred to the Congo red staining solution (a 80% ethanol 
saturated NaCl solution with 0.2 g Congo red per 100 ml) for 25 min, the slides are rinsed 
quickly in distilled water and air dried. Thiazine red (Uchihara et al, 2000) slides with 
sections are rinsed in distilled water for 5 min, and put in the Thiazine red solution (0.1g 
Thiazine red in 300 ml 0.001 M Naphosphate buffer, pH 7.4) for 15 min. Then the slides are 
rinsed quickly twice in distilled water and air dried, when dry they are coverslipped with 
DPX. Methoxy-XO4 staining, slides with sections are rinsed in distilled water for 5 min, and 
put in the Methoxy-XO4 solution (3.3 mg Methoxy-XO4 in 100 ml 40% ethanol/60%distilled 
water at pH 10.00) for 10 min. Then the slides are rinsed quickly twice in distilled water and 
air dried, when dry they are coverslipped with DPX.  
3. Results  
3.1 In vitro staining  
The staining of sections of paraformaldehyde fixed brains of AP/PS mice with histochemical 
methods revealed that all methods that are used for staining amyloid also stain amyloid ǃ 
and stained all dense Aǃ deposits, i.e., plaques (Figure 1). However, it should be noted that 
in the sections of the AP/PS mice that have large amounts of diffuse Aǃ deposits, most these 
deposits were not stained. Staining intensity of the Aǃ deposits was directly related to the 
method that was used, the solutions that we used contained the optimal concentrations of   
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Fig. 1. Eight photomicrographs of coronal sections of the hippocampal formation of a Tg AD 
model mouse brain. A, section stained with thioflavine-S; B, section stained with Congo red; 
C, section stained with thiazine red; D, section stained with methoxy-X0; E, section stained 
with thioflavine-T; F, section stained with cresyl violet (Nissl stain), G, section stained with 
D3, and H, section stained for Aǃ . 
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dye for these sections. They have the highest concentration that stains optimally in the 
shortest time. Longer time periods increased the background staining and did not improve 
staining quality (i.e., the signal/noise ratio; not illustrated). 
The staining of sections of paraformaldehyde fixed brain sections of AP/PS mice with the 
three D-peptides revealed that all peptides (i.e., D1-D3) bound to all dense Aǃ deposits, i.e., 
plaques (Figure 2). However, it should be noted that in the sections of the AP/PS mice that 
have large amounts of diffuse Aǃ deposits, these deposits were not stained (Figure 1). 
Staining intensity of the Aǃ deposits was directly related to both the D-peptide 
concentration that was tested (0.01, 0.001 and 0.0001 mg/ml), with the highest concentration 
staining optimally in the shortest time. At the highest concentration the optimal staining 
time was less than 5 min (i.e., with the best signal/noise ratio), whereas at the lowest 
 
 
Fig. 2. Nine high power photomicrographs of adjacent coronal sections through the parietal 
cortex of an 18-month-old APP/PS1 mouse. The top six photomicrographs demonstrate the 
typical staining of plaques and blood vessels with respectively, D1, D2, and D3. The lower 3 
photomicrographs show the typical staining of L-D1, sc-D1, and L3, respectively. Please 
note the lack of staining by the scrambled D-peptide (sc-D1), arrowhead indicates plaque 
core 
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concentration (0.0001 mg/ml) the time was more than 6 hours. Longer time periods 
increased the background staining and did not improve staining quality (i.e., the 
signal/noise ratio). It should be noted that with the lower concentrations, and appropriate 
longer staining time, the amount of non-specific staining (i.e., background) was significantly 
decreased. Similarly, post-staining rinsing of the stained sections in buffer decreased the 
amount of background staining, but even 24 h washing in buffer did not change the 
intensity of the specific binding.  
Further, in general, the D3 peptide gave rise to slightly higher levels of specific staining than 
the D1 peptide. Further, very little Aǃ was stained in the AP mouse brain sections, but the 
APP mutation in these mice is in the Aǃ sequence and thus leads to Aǃ proteins with a 
different amino acid sequence. 
Comparison of the D-peptide stainings with the amyloid staining with Aǃ40 and Aǃ42 
antibodies of sections of the AP/PS and AP/PSΔ mouse brains showed that there was nearly 
complete overlap between the location of Aǃ42 staining (i.e., plaques) and the D-peptide 
binding (Figure 3; van Groen et al, 2009). Similarly, comparison of the immunohistochemical 
staining of the adjacent sections for human amyloid ǃ (with the W0-2 antibody which is 
specific for human Aǃ4-10 sequence) showed that there was complete overlap between the 
location of dense Aǃ staining (i.e., plaques) and the binding of the three D-peptides (D1-D3), 
but that the diffuse amyloid ǃ deposits were not stained, neither in the hippocampus or in 
the cortex (Figure 1).  
 
 
Fig. 3. Four high power photomicrographs of coronal sections through the hippocampus of 
a Tg AD model mouse. Sections were stained for D3, Aǃ40, Aǃ42, and Aǃ, respectively. 
Please note the correspondence between D3 and Aǃ42 stained sections. 
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Immunohistochemical staining for Aǃ40 or Aǃ42 of the sections that were adjacent to the 
sections stained with the D-peptides showed that the distribution of the D-peptides 
corresponded more closely to the distribution of Aǃ42 than to the distribution of Aǃ40 
labeling (Figure 3). Both Aǃ42 and D3 stain predominantly the core of the plaques, whereas 
Aǃ40 stains mainly the outside of the plaques, i.e., the rim (Figure 3). Sections that were 
double-stained for both Aǃ42 and the D-peptide demonstrated a total overlap between the 
site of dense Aǃ42 deposits and the location of D1 and D3 (not illustrated). Furthermore, 
staining with ǃ-sheet markers such as thioflavine-S, Congo red, or thiazine red revealed that 
all Aǃ deposits with a ǃ-sheet positive core also stained with the D-peptides (Figure 1). The 
staining of fixed brain sections of Tg AD model mice (APP-PS) from different ages revealed 
that in old mice (over 18 months of age), when blood vessel walls contain some Aǃ42 
deposits, they were stained by the D1 and D3 peptides (Figure 2), but not by the D2 peptide. 
It should be noted that at earlier ages only Aǃ40 is found in the blood vessel wall, and that 
at that age no labeling with D-peptides is present. Labeling of sections of non-transgenic 
littermates or control animals did not show any staining at any place in the brain.  
To analyze further the binding characteristics of the D-peptides in more detail, an L-peptide 
version of the D1-peptide (i.e., L-D1) was also tested, likewise a scrambled (sequence) 
peptide of similar amino acid length (i.e, sc-D1) was tested (Table 1). We used both 0.001 
and 0.0001 mg/ml concentrations of L-D1 and sc-D1 on fixed brain sections of old (18 
months of age) AP/PS mice. L-D1 bound quite similarly to Aǃ deposits compared to its D-
peptide analog, i.e., it labeled dense Aǃ deposits, but not diffuse deposits, and it lightly 
labeled blood vessel walls with showed Aǃ deposits. It should be noted that similar 
amounts of the L-peptide showed less labeling compared to the D1 peptide. Finally, in 
contrast to both the L- and D-peptide, the sc-D1 peptide showed significantly reduced 
binding to Aǃ at any type of amyloid deposit (Figure 3). Further, we tested a peptide that 
was generated against the L-form of Aǃ42, i.e., L3, this peptide showed very similar 
characteristics to the D3 peptide. 
In these binding experiments all peptides that were used had been conjugated with a FITC 
molecule for visualization purposes, therefore we tested in a final set of experiments 
whether the D1 conjugated with different fluorophores would show distinct binding 
characteristics, i.e., study the interaction of the fluorescent moiety with the Aǃ binding. The 
data show that no differences in specific binding are present at the 0.001 and 0.0001 mg/ml 
concentrations between these D-peptides (Figure 4). The D1 conjugated to Oregon green, 
which is similar in size and charge to FITC, bound Aǃ42 similar to the D1*FITC, but the 
D1*Bodipy (Bodipy is smaller and more polar than FITC) showed significantly increased 
background staining (Figure 4). 
 
Peptide Sequence Description 
D1 qshyrhispaqv Dominating sequence selection 1, Target: D-Aǃ 
L-D1 QSHYRHISPAQV L-enantiomer of D1 
sc-D1 hsspqivhqayr Scrambled D1 
D2 giswqqshhlva Dominating sequence selection 2, Target: D- Aǃ 
D3 rprtrlhthrnr Dominating sequence selection 3, Target: D- Aǃ 
L3 LRMMLQIKRIPR Dominating sequence selection 3, Target: L- Aǃ 
Table 1. Showing the nomenclature and amino acid sequence of the peptides used in this 
study. 
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Fig. 4. Three photomicrographs of coronal sections of the parietal cortex of an 18-months-old 
APP/PS1 mouse stained with the D1 peptide conjugated with different fluorophores, 
showing staining with D1*FITC, D1*Bodipy, and D1*Oregon green, respectively. Please note 
the increased background staining with the D1*Bodipy, also note similarity of staining 
between D1*FITC and D1*Oregon green. 
4. Discussion 
In this study we compared the staining characteristics of three small D-amino acid peptides 
(i.e., D1, D2, and D3) that were designed to specifically bind Aǃ42 (D1, Wiesehan and 
Willbold, 2003; Wiesehan et al., 2003; D3, ) with the two traditional histochemical methods 
for amyloid (thioflavine-S and Congo red) and two newer techniques. We examined the 
labeling of Aǃ deposits in Tg AD model mouse brain, in the hippocampus, cortex and in 
blood vessel walls. The data demonstrate that all dense Aǃ deposits (plaques) are labeled 
with the D-peptides, but not diffuse deposits. This corresponds to the distribution of the Aǃ 
staining in the brain when it is labeled with Aǃ42 specific antibodies. Finally, the binding of 
the D-peptides corresponds closely to the localization of Aǃ42 in the brain, more closely 
than to the localization of Aǃ40. 
Similarly, in brain tissue sections derived from AD patients, amyloid ǃ plaques and 
leptomeningeal vessels containing Aǃ are stained positively with the fluorescence-labeled 
derivative of D1 (Wiesehan et al, 2003). In contrast, fibrillar deposits derived from other 
amyloidosis are not labeled by D1 (Wiesehan et al, 2003). It should be noted that none of the D-
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peptides showed any binding to Aǃ deposits in the brains of mice which express the 
APPswe/dutch/iowa mutation van Groen et al, 2009). This is to be expected since the 
structure of the Aǃ peptide with these mutations (i.e., the Dutch and Iowa mutations) is 
predicted to be different from the “normal” Aǃ peptide (Demeester et al., 2001; Kumar-Singh 
et al., 2002; Tsubuki et al.,  2003; Watson et al., 1999). It should be noted that these mutations 
are in the Aǃ peptide sequence of APP, in contrast to the Swedish mutation (Selkoe, 2001). 
The data demonstrate that none of the three D-peptides binds to diffuse Aǃ deposits, 
whereas they do bind to dense Aǃ deposits, i.e., plaques. Earlier we have shown that the 
diffuse Aǃ deposits do not stain with thioflavine S, Congo red or thiazine red, whereas the 
core of plaques does. Furthermore, the diffuse deposits consist primarily of N-terminal 
fragments of Aǃ, they contain some Aǃ40 but do not contain stainable amounts of Aǃ42 
(Van Groen et al., 2003), in contrast to plaques that consist of significant amounts of both 
Aǃ40 and Aǃ42. We have suggested earlier that the diffuse deposits consist of Aǃ that has a 
different length (and structure) from the Aǃ42 and Aǃ40 that is present in plaques, even if 
Aǃ fibrils are present in the diffuse deposits (Van Groen et al., 2003). Together these data 
indicate that the D-peptides bind very specifically to only Aǃ42. 
Furthermore, it has been shown that Aǃ42 is actively taken up by astrocytes and microglia 
(Nagele et al., 2003; Rogers and Lue, 2001. In contrast, surprisingly, no D-peptides are 
visible in astrocytes and microglia, the phagocytosing cells in the brain (Rogers et al, 2002). 
Activated microglial cells are present in the brains of AD model mice but these cells never 
show any presence of intracellular Aǃ (e.g., Stalder et al., 2003; but see Paresce et al., 1996).  
We have used these peptides to treat AD model mice and we have shown that a brain 
infusion with D3 significantly reduces pathology and cognitive deficits in AD model mice 
(van Groen et al, 2009, Funke et al, 2011). In contrast D1 infusion does not improve cognition 
(van Groen et al, 2009). Similarly it has been demonstrated that Congo red (Inouye and 
Kirschner, 2005, Lee, 2002) and thioflavine-S improve pathology (Alavez et al, 2011). 
Together, we have demonstrated that 1) D-peptides that specifically bind to Aǃ42 and, 2) 
that the D-peptides staining is similar, but more specific, to most traditional histochemical 
amyloid staining methods. Thus, our data strongly suggest that these novel and highly 
specific Abeta42 ligands have potential application(s) in the diagnosis and therapy of 
Alzheimer's disease (Masters and Beyreuther, 2006; Monaco et al., 2006), especially since 
these D-peptides are much more resistant to proteolysis than natural L-peptides.  
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